Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The expansion of research and development efforts in the pharmaceutical and biotechnology sector, aimed at addressing the increasing requirements for treating various chronic diseases, is fueling the growth of the PEGylated drugs market. A survey conducted among members of the Pharmaceutical Research and Manufacturers of America (PhRMA) revealed substantial investments in research and development. In 2017, PhRMA member companies collectively invested a noteworthy USD 71.4 billion in R&D. Notably, the majority of this R&D spending, estimated at USD 90 billion, came from the United States.
Highlighting the global scope of these efforts, the Association of the British Pharmaceutical Industry (ABPI) invested over USD 418 million in the UK alone for research and development. Their focus was on seeking breakthroughs for conditions like cancer, dementia, and rare genetic diseases. Similarly, the Australian government allocated over USD 174.8 million in 2017 for cancer research and development, as reported by the National Health and Medical Research Council. This significant increase in research and development activities within the healthcare sector is contributing to the upward trajectory of PEGylation technology.
The advancements in research and development within the pharmaceutical industry play a pivotal role in propelling the growth of the PEGylated drugs market. These efforts are a response to the growing demand for effective treatments for chronic diseases, and they signify a commitment to discovering innovative solutions to address the complexities of various health conditions.
The investment figures provided by PhRMA underscore the substantial financial commitment made by pharmaceutical companies towards advancing healthcare solutions. The focus on research and development is not limited to a single region, as evidenced by the global investments reported by ABPI and the Australian government. This concerted effort reflects the recognition of the challenges posed by chronic diseases and the determination to find solutions that can make a positive impact on patients' lives.
As the pharmaceutical and biotechnology industry continues to channel significant resources into research and development, the resulting innovations are driving the growth of the PEGylated drugs market. PEGylation technology, in particular, is gaining prominence due to its ability to enhance drug delivery and improve the efficacy of treatments. The market's upward trajectory is a testament to the transformative impact of ongoing research and development initiatives in the field of healthcare.
In conclusion, the surge in research and development activities within the pharmaceutical and biotechnology industry is a key driver behind the growth of the PEGylated drugs market. The substantial investments made by organizations globally underscore a commitment to addressing the challenges posed by chronic diseases. As advancements in healthcare solutions continue to emerge, propelled by dedicated research and development efforts, PEGylation technology is positioned for increased adoption, offering promising outcomes for the treatment of various health conditions. The ongoing commitment to innovation signals a positive trajectory for the PEGylated drugs market, driven by the collective efforts to enhance the quality of healthcare worldwide.
PEGylated Drugs Market Highlights:
PEGylated Drugs Market Overview
Pegylated Drugs Market Size was valued at USD 7.41 Billion in 2023. The Global Pegylated Drugs industry is projected to grow from USD 8.16 Billion in 2024 to USD 17.80 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.25% during the forecast period (2024 - 2032).
Pegylated is the attachment process of covalent and non-covalent glycol polymer chains with bioactive molecules such as peptides, proteins, antibody fragments, enzymes and oligonucleotides etc. It is safe technique that is used in increasing the therapeutic efficiency of medicines in a clinical atmosphere. There are many fda approved pegylated drugs used for clinical purpose.
All the prominent key players are investing in R&D and Merger & Acquisitions. The key players have a plenty of molecules as their future projects.
The report comprises of detailed discussion on the benefit of the pegylated antibody, its market growth, driving factors and challenges. Also, it puts light on the major key players and their contribution and development in the PEGylated Proteins Market.
PEGylated Drugs Market dynamics
Drivers
The main driving force behind the growth of the PEGylated Drugs Market are, the rising of prevalence diseases such as cancer, advancement of biologics sectors, and increasing pharmaceutical industries all across the globe. Additionally, the increasing number of chronic ailments and death rates because of cancer in Canada will provide a boost to the growth of the pegylated drugs on market.
Challenges
Although the benefits of pegylated drugs are many, but there are some backdrops available as well with it. The side effects happening because of the drugs and the drug failure will make a restraining effect against the growth of the PEGylated Proteins Market during the forecast period.
Cumulative growth
PEGylated Drugs mainly have three benefits on the body.
- Pharmacokinetics and pharmacodynamic properties Improvement
According to studies, the pharmacokinetic properties drastically changes in the body along with prolonging the plasma half-life; it also increases the release of drugs in the body and reduces the renal clearance rate.
- Drug stability enhancement
A thicker hydration film forms on the surface preventing the precipitation and aggregation. The liposome stability is also increased by the modified linkage between lipid derivatives and PEG. Additionally, the flexible chain of PEG produces a hindrance effect which is steric protecting the modification from protease attack increasing the stability of the modification.
- Drug distribution improvement in the body
The molecular weight of the drugs increases in the body after being modified by PEG that help reducing the glomerular filtration effects during systemic administration. Therefore, it increases the excretion in the urination. Moreover, PEGylated drugs are also responsible for improving the stability in the systemic circulation and prolongs retention time which is highly beneficial in the distribution of the drugs in one's body. Particularly it helps in accumulating macromolecular drugs in inflammatory sites and tumours. Therefore, it increases the span of treatment of the drugs in vivo.
PEGylated Drugs Market Segmentation overview
Based on the PEGylated Drugs Market, it is segmented into-
- Molecule
- Indication
- Region
PEGylated Drugs Market, By Molecule
Based on molecule, the PEGylated Proteins Market is further segmented into-
- Protein
- FAB’ Fragment
- Enzyme
- Aptamer
PEGylated Drugs Market, By Indication
Based on indication, the PEGylated Proteins Market is further segmented into
- Cancer
- Gout
- Hemophilia
- Hepatitis
Cancer segment had 60% of the PEGylated Drugs Market share in 2017 owing to the increasing prevalence of diseases that demanded for a development in making effective drugs. The hepatitis segment is expected to grow at a CAGR of 12% over the forecast period. Moreover, the major key players focusing and developing the pegylated drugs using in chronic disease treatments will propel the growth of the market. For example, the market will be highly benefited with the launch of Pegasys drugs used for the treatment of Hepatitis C in adult patients.
PEGylated Drugs Market, by Region
Based on region, the PEGylated Drugs Market is further segmented into-
- North America
- US
- Canada
- Latin America
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia & New Zealand
- Southeast Asia
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
PEGylated Drugs Market Regional analysis
Globally, the regional PEGylated Drugs Market is divided into Americas, Europe, Asia-Pacific and Middle East and Africa.
The American market is divided into North America and South America. The American market had a market share of 65.73% in 2018. U.S and Canada are the dominating region of the North American market. Canadian PEGylated Drugs Market is expected to witness a market growth of over 5.5% CAGR during the forecast period. The rising in the prevalence of chronic diseases such as cancer is driving the growth of the market. In 2017, more than 2lac people were diagnosed with cancer (as per the report of Canadian Cancer Society) which had emerged the demand of the pegylated drugs in the market.
Europe was the second-largest market in 2018. The European government supporting and investing in reducing chronic diseases is the driving force behind the growth the regional market. The European region is further classified into Western Europe and Eastern Europe. Western Europe is also classified into the UK, Italy, France, Spain and the rest of the Western Europe. Italian PEGylated Drugs Market had a revenue of USD 218 million in 2017 and expected to witness a growth at a CAGR of 9% during the forecast period.
The Asia-Pacific region is further clssified into India, China, Japan, Australia, South Korea and the rest of Asia-Pacific. APAC holds the third-largest position in the regional PEGylated Drugs Market.
The Middle East and Africa is anticipated to witness a significant growth due to the rising application of pegylated drugs for treating the chronic diseases.
Competitive landscape
Few industry key players operating the market growth are investing in R&D in PEGylated technology is providing a huge boost in the growth of the PEGylated Drugs Market.
Recent developments
In recent times, new PEGylated drugs such as modified drugs using heterobifunctional PEG (X-PEG-Y) as a linker have been launched with the continuous deep research and developments. It is also believed that in future, the continuous modification in the technology will produce more and more effective and better drugs.
Major key players
There are several major key players in the market. The players operating in the PEGylated Drugs Market are focusing on developing and launching new products and expanding their footprints in the global and larger markets.
- Horizon Therapeutics Plc • F. Hoffmann-La Roche Ltd. • Pfizer Inc. • Novo Nordisk A/S • UCB S.A. • Amgen, Inc. • AstraZeneca. • Merck & Co., Inc. • Takeda Pharmaceutical Company Limited • Bayer AG • Biogen • BioMarin Pharmaceutical Inc • Coherus BioSciences • Enzon • Leadiant Biosciences, Inc.
Report Overview
The report comprises of
- Market overview
- Covid-19 impact
- Market dynamics
- Drivers
- Challenges
- Restrains
- Opportunities
- Technological analysis
- Segmentation overview
- Regional analysis
- Competitive landscape
- Recent developments
- Major key players
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
